Valneva (VALN) has released an update.
Valneva SE, a specialty vaccine company, is conducting an investor day in New York City to showcase its Lyme disease vaccine candidate VLA15, developed with Pfizer, and discuss its commercial vaccine business and R&D pipeline. The event features presentations from the senior leadership and includes a financial overview and future outlook, with a focus on achieving sustained profitability from 2027 driven by its travel vaccines and ongoing R&D efforts.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
